Renaissance Technologies (RenTech)'s IBRX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 1.23 M shares of ImmunityBio, Inc. (IBRX) worth $2.44 M, representing 0.00% of the portfolio. First purchased in 2021-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in IBRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 1.02 M shares. Largest reduction occurred in Q3 2022, reducing 401,681 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s ImmunityBio (IBRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly ImmunityBio (IBRX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +215,571 | Add 21.21% | 1.23 M | $1.98 |
| Q3 2025 | +1.02 M | New Buy | 1.02 M | $2.46 |
| Q3 2022 | -401,681 | Sold Out | 0 | $0.00 |
| Q2 2022 | +401,681 | New Buy | 401,681 | $3.72 |
| Q1 2022 | -304,900 | Sold Out | 0 | $0.00 |
| Q4 2021 | +96,983 | Add 46.65% | 304,900 | $6.08 |
| Q3 2021 | +207,917 | New Buy | 207,917 | $9.74 |
Renaissance Technologies (RenTech)'s ImmunityBio Investment FAQs
Renaissance Technologies (RenTech) first purchased ImmunityBio, Inc. (IBRX) in Q3 2021, acquiring 207,917 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held ImmunityBio, Inc. (IBRX) for 7 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to ImmunityBio, Inc. (IBRX) was in Q3 2025, adding 1,016,199 shares worth $2.5 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 1,231,770 shares of ImmunityBio, Inc. (IBRX), valued at approximately $2.44 M.
As of the Q4 2025 filing, ImmunityBio, Inc. (IBRX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in ImmunityBio, Inc. (IBRX) was 1,231,770 shares, as reported at the end of Q4 2025.